Pre-earnings brief
Reports
Mon, Feb 28, 2022
Est. EPS
—
Est. revenue
—
Implied move
±25.0%
EPS beat rate
14%
Grifols, S.A. is a global healthcare company specializing in biotechnology, particularly in the production of plasma-derived medicines. With a market cap of $5 billion, it plays a crucial role in treating various medical conditions, making it significant in the health care sector.
Last quarter
In Q2-2021, Grifols reported an EPS of $0.24, falling short of the expected $0.27. The stock reacted positively, gaining 1.76% the following day.
EPS beat streak
0Q
EPS beat rate
14%
Avg EPS surprise
-3.86%
Avg 1-day reaction
+1.41%
Overall, expectations for Grifols this quarter are mixed, with no clear consensus on earnings or revenue performance. The market is likely weighing recent performance trends against broader industry challenges.
Bull case
Optimistically, if Grifols can demonstrate strong demand for its plasma-derived products and improve its margins, it could see significant stock appreciation.
Bear case
Conversely, if the company fails to meet earnings expectations again or reports weak revenue growth, it could face downward pressure on its stock price.
The print will turn on these.
Q1
What will the EPS be this quarter, and how does it compare to previous quarters?
Given the company's recent EPS misses, investors will closely scrutinize this figure to gauge financial health and operational efficiency.
Q2
How is Grifols addressing supply chain challenges and demand for plasma-derived products?
With ongoing global supply chain issues, understanding how Grifols is managing these challenges will be critical for future growth prospects.
Why consensus could be wrong
The Street may underestimate Grifols' ability to recover from recent operational challenges, especially given the increasing demand for plasma-derived therapies.
Supporting evidence
Options pricing suggests a 24.97% move, indicating heightened expectations that may not align with historical performance.
The company's recent stock performance has shown resilience despite earnings misses, suggesting a potential turnaround.
Grifols has a strong product pipeline that could drive future growth, which may not be fully reflected in current market sentiment.
Key risk
If the EPS comes in above $0.30, it could significantly shift market sentiment and expectations.
Pre-commit to what would confirm each case.
This quarter's performance will hinge on Grifols' ability to improve its earnings and manage operational challenges effectively.
Bull confirmed if
An EPS of $0.30 or higher would confirm the bull case, indicating a turnaround in profitability.
Bear confirmed if
An EPS below $0.20 would confirm the bear case, suggesting ongoing struggles in meeting market expectations.
What the market is pricing for the move.
Implied Move
±24.97%
Historical Avg
±1.5%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.
Options are pricing ±25.0% while GRFS has averaged ±1.5% over the last 7 prints — setup is pricing rich.
30d HV
19.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Grifols beats expectations, history suggests a potential stock increase of around 0.10% on the first day, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
If the company misses earnings expectations, history suggests a potential decline of about 1.35%, indicating investor disappointment.
The lines on the call that would change the story.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—